Septerna (NASDAQ:SEPN) Earns Buy Rating from Analysts at TD Cowen

Analysts at TD Cowen began coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating on the stock.

Septerna Price Performance

Shares of NASDAQ:SEPN opened at $23.55 on Tuesday. Septerna has a fifty-two week low of $18.62 and a fifty-two week high of $26.34.

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the company’s stock in a transaction on Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the acquisition, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.